Navigation Links
CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2013

ATLANTA, Nov. 21, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the fourth quarter 2013 of $0.0275 per share of common stock outstanding.  The quarterly cash dividend of $0.0275 per share will be paid on December 20, 2013 to all common stockholders of record as of December 13, 2013.  The ex-dividend date for the quarterly dividend is December 11, 2013. 

CryoLife anticipates paying quarterly dividends in March, June, September, and December of each year.  Based on the number of shares currently outstanding, the Company currently expects to pay a total annual dividend of approximately $3.0 million.  These statements represent management's current beliefs and expectations and are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. As such, they are subject to risks and uncertainties that could cause future events to deviate from current expectations, including without limitation that the declaration of future dividends and the establishment of the per share amount, record dates, and payment dates for future dividends are subject to final determination by the Company's Board of Directors, and will be dependent upon future earnings, cash flows, financial and lender requirements, the Board's evaluation of competing uses for available cash, and other factors.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S., certain countries in Europa, and Canada.  CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia.  CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.  CryoLife's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections.  Additional marketing approvals for BioGlue have been granted in several other countries throughout the world.  CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR).  In addition, CryoLife and its subsidiary Hemosphere, Inc. market the HeRO® Graft, which is a solution for end-stage renal disease in certain hemodialysis patients.  CryoLife distributes PerClot®, an absorbable powder hemostat, in the European Community and other select international countries.  CryoLife's BioFoam® Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. 

For additional information about CryoLife, visit CryoLife's website,



D. Ashley Lee

Executive Vice President, Chief Financial Officer

and Chief Operating Officer

Phone: 770-419-3355

The Ruth Group

Nick Laudico / Zack Kubow

646-536-7030 / 7020

SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife To Host Second Central Venous Pathology Summit in 2013
2. CryoLife To Host Aortic Valve and Root Training Session
3. CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2013
4. CryoLife kündigt erste Implantation des HeRO Transplantats in Europa an
5. CryoLife anuncia el primer implante europeo del injerto HeRO
6. CryoLife annuncia il primo impianto europeo di HeRO Graft
7. CryoLife Announces First European Implant Of HeRO Graft
8. CryoLife Reports Record Second Quarter Revenues
9. CryoLife Announces Release Date and Teleconference Call Details for 2013 Second Quarter Financial Results
10. CryoLife Enhances International Presence with Appointment of Andres Sarmiento as Latin America Sales Manager
11. CryoLife 2013 First Quarter Revenues Grew 10 Percent to a Record $35.5 Million
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The ... prided itself for not only fulfilling the needs of advisers and clients but ... affordable price and providing top-tier customer service. However, there's always room for improvement, ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... largest, most successful and prominent nonprofit healthcare organizations in the country. They have ... with various organizations, and helped advance the healthcare industry as a whole through ...
(Date:11/27/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk ... Term Support) into its Q-Suite 5.10 product line. , Making the change to ... of Asterisk that will receive not only security fixes, but feature and bug ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge Memorial ... in the Waterloo region. Using the Ocean Platform, family physicians can now order ... electronic medical record (EMR) without the need for redundant patient entry or an ...
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical laboratories and in the ... healthcare staffing agency Aureus Medical Group . These fields, as well ... those searching for healthcare jobs through the company’s website, , The ...
Breaking Medicine News(10 mins):